Baxter Belgium Manufacturing SA (secondary packaging of finished medicinal product and solvent, partial quality control of finished medicinal product, batch release of finished medicinal product and solvent)
UkraineAll drugs from this manufacturer
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage recombinant human blood coagulation factor viii octocog alfa 250 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage recombinant human blood coagulation factor viii octocog alfa 500 IU ATC: B02BD02
-
The drug is intended for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage recombinant human blood coagulation factor viii octocog alfa 1000 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage recombinant human blood coagulation factor viii octocog alfa 1500 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage recombinant human blood coagulation factor viii octocog alfa 2000 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage recombinant human blood coagulation factor viii octocog alfa 3000 IU ATC: B02BD02